ARTICLE | Clinical News
Serelaxin: Development discontinued
April 28, 2017 8:06 PM UTC
Novartis said it discontinued development of serelaxin. In March, serelaxin missed the co-primary endpoints in the Phase III RELAX-AHF-2 trial to treat AHF (see BioCentury, March 24)...
BCIQ Target Profiles